Replies to post #140958 on Biotech Values

[DewDiligence]

TGTX addendum for amusement—a few years ago, the company claimed to have a non-insecticide treatment for head lice:

http://ir.manhattanpharma.com/releasedetail.cfm?ReleaseID=278896

Hedrin is a unique, proprietary combination of silicones (dimeticone [sic] and cyclomethicone) that acts as a pediculicidal (lice killing) agent by disrupting the insect's mechanism for managing fluid and breathing. Hedrin contains no traditional chemical insecticides in contrast with most currently available lice treatments… Because Hedrin kills lice by preventing the louse from excreting waste fluid and by asphyxiation (smothering), rather than by acting on the central nervous system, the insects cannot build up resistance to the treatment.

[mcbio]

p.s. The CEO of TGTX is the infamous Michael Weiss.

What is the back story here behind Michael Weiss? I'm not familiar with his history. I ask because TGTX came up on my Twitter stream today and they have a 3rd gen Rituxan in the clinic to go along with a PI3K delta drug about to enter the clinic all for about a $50M market cap. At the recent Oppenheimer presentation, they talked about the ability to combine the 3rd gen Rituxan with the PI3K. Also talked about potential advantages of their PI3K delta over the GILD PI3K delta. They claim they have 18-21 months of cash as well. Doesn't exactly seem to be an expensive stock but it sounds like there's also a checkered history here for this company and presumably some reasons to be skeptical.

[BTH]

The odd thing about this company is Mark Schoenbaum of ISI is on the Board.

I have a very tiny speculative long position simply because of the hot PI3K-delta drug; yes, not data, all hype ---- which is why it's a tiny position. But Mike Weiss certainly fleeced many with Sulonex pumping that one with Keryx.